Sera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Sera Prognostics (NASDAQ:SERA) released its quarterly earnings data on Wednesday. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.01), FiscalAI reports. Sera Prognostics had a negative net margin of 39,417.29% and a negative return on equity of 37.50%. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.07 million.

Here are the key takeaways from Sera Prognostics’ conference call:

• Launched a third partnership program (reaching over 350 providers across three states) and is engaging with 13 payers in 15 states, pursuing a paced rollout of ~one large partner program per quarter to drive provider adoption and referral pathways for PreTRM.
• Strengthened the evidence base after publication of the full PRIME trial and related European commentary, with the PREPARE survey accepted for publication and multiple PRIME sub‑analyses (including health economics and Medicaid outcomes) planned for 2026 to support reimbursement and guideline inclusion.
• Financial performance remains modest: Q1 revenue was just $14,000 (down from $38,000 a year ago) and net loss was $8.4 million, and management cautioned 2026 revenue may stay uneven as commercialization and reimbursement efforts ramp.
• Completed a business realignment to shift spend toward commercialization and medical engagement, targeting nearly $10 million in annualized operating expense reductions and reporting $86.8 million in cash and securities with an expected cash runway through 2029.
• Strategic pivot reduces internal R&D/Clinical Ops headcount and emphasizes external partnerships to develop future tests, a move that could speed market access but also lowers internal development capacity until new collaborations are formalized.

Sera Prognostics Stock Up 6.1%

SERA traded up $0.11 during midday trading on Thursday, hitting $1.92. 118,500 shares of the company were exchanged, compared to its average volume of 52,125. The firm has a market capitalization of $75.15 million, a P/E ratio of -2.82 and a beta of 0.92. Sera Prognostics has a 1-year low of $1.37 and a 1-year high of $4.09. The firm’s 50 day moving average price is $2.05 and its 200-day moving average price is $2.76.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Sera Prognostics in a report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Insider Buying and Selling

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 22,639 shares of Sera Prognostics stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $1.90, for a total transaction of $43,014.10. Following the transaction, the chief executive officer directly owned 741,287 shares of the company’s stock, valued at approximately $1,408,445.30. The trade was a 2.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders sold 53,133 shares of company stock worth $103,854. 11.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Lido Advisors LLC acquired a new position in Sera Prognostics during the 3rd quarter worth about $68,000. Cetera Investment Advisers acquired a new position in Sera Prognostics during the 4th quarter worth about $74,000. Qube Research & Technologies Ltd acquired a new position in Sera Prognostics during the 2nd quarter worth about $92,000. Two Sigma Investments LP acquired a new position in Sera Prognostics during the 3rd quarter worth about $97,000. Finally, Barclays PLC lifted its holdings in Sera Prognostics by 267.4% during the 4th quarter. Barclays PLC now owns 36,722 shares of the company’s stock worth $108,000 after buying an additional 26,726 shares during the period. 54.64% of the stock is owned by institutional investors and hedge funds.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.